LOL! preclinical trial started in March! While some keep claiming it would never happen! LOL! Word! Check it out preclinical trials started Mar 15 2022 Submitted 15 Mar 2022 Preclinical trials in Myelodysplastic syndromes in USA (IV) (Regen Biopharma pipeline) 10 Mar 2022 Preclinical development in Breast cancer and Myelodysplastic syndrome is ongoing USA Stay tuned much more on the way!
I can’t wait for the FDA Fast Track! It also Looks like our NR2F6 human patent was finally granted! While some claimed it would never happen LoL! Patent Grant 11241427 U.S. patent number 11,241,427 [Application Number 15/364,111] was granted by the patent office on 2022-02-08 for small molecule modulators of nr2f6 activity. This patent grant is currently assigned to KCL Therapeutics, Inc.. The grantee listed for this patent is Regen Biopharma, Inc.. Invention is credited to Thomas Ichim, David Koos. FDA already granted HemaXellerate and human study was successful. nr26f patent granted The other IND activation filed is a shoe in. No if ands or Butts about it. RGBP has a Dream team of scientific professionals working for team RGBP and it’s not if but when! LoL! Past human studies where also Successful! LOL! While some claimed they would never happen or the IND’s would not get approved! LoL! https://www.prnewswire.com/news-releases/pan-am-cancer-treatment-center-provides-final-hemaxellerate-clinical-data-to-regen-biopharma-inc-for-treatment-of-bone-marrow-suppression-study-598169731.html
In the latest data presented, the patients who apparently benefited after one month maintained their high levels of white blood cells and all 5 patients had increased numbers of white blood cells after 6 months as compared to after 1 month. In addition, all 5 patients had increased numbers of red blood cells and increased numbers of platelets 6 months after treatment as compared to after 1 month.
Now RGBP has much more going for us! Regen BioPharma Inc's Company Profile Business Description Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
News 
Market Data 
Discover 
